PAN-90806 is under clinical development by PanOptica and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PAN-90806’s likelihood of approval (LoA) and phase transition for Wet (Neovascular / Exudative) Macular Degeneration took place on 04 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PAN-90806 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PAN-90806 overview

PAN-90806 is under development for the treatment of diabetic macular edema, wet AMD, neovascular age-related macular degeneration (neovascular AMD). It is formulated as suspension and administered as ophthalmic drops. The drug candidate selectively targets VEGF receptor. It was under development for the treatment of proliferative diabetic retinopathy as a solution formulation.

PanOptica overview

PanOptica is a clinical-stage biopharmaceutical company that develops topical eye drops for the treatment of sight-threatening eye diseases. The company concentrates on candidates that are at or near the investigational new drug application stage. It develops PAN-90806, a novel, topically applied, once daily eye drop for the treatment of wet AMD and other neovascular eye diseases. PanOptica’s drugs are used in sight-threatening eye diseases caused by abnormal or leaky blood vessels. The company also partners biopharmaceutical companies to complete development, regulatory approval, and commercialization of the compound. PanOptica is headquartered in Bernardsville, New Jersey, the US.

Quick View PAN-90806 LOA Data

Report Segments
  • Innovator
Drug Name
  • PAN-90806
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Metabolic Disorders
  • Ophthalmology
Key Developers
  • Sponsor Company: PanOptica
  • Originator: OSI Pharmaceuticals
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.